Jeffrey Finer

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C.

Transcriptic, Inc. engages in the conversion of biology into an information technology, driven by data, and computation. It specializes in biology, automation, and software engineering. The company was founded by Max Joseph Hodak on February 14, 2012 and is headquartered in Menlo Park, CA.

Ambys Medicines, Inc. develops regenerative medicine therapies for serious liver diseases. The company was founded by Martin Burke, Markus Grompe, Juan Carlos Izpisua Belmonte and Holger Willenbring and is headquartered in South San Francisco, CA.

Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA.

Strateos engages in the automation of chemistry, biology, and tissue analysis into closed loop robotic laboratories that support drug discovery programs. The company is headquartered in the Menlo Park, CA.

Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation.